On April 12, 2018 GamaMabs Pharma, a biotechnology company developing optimized therapeutic antibodies targeting AMHRII for the treatment of cancer, reported the presentation of two posters on its AMHRII program at the upcoming American Association for Cancer Research (AACR) (Free AACR Whitepaper) annual meeting, taking place from April 14 to 18 in Chicago, USA (Press release, GamaMabs Pharma, APR 12, 2018, View Source [SID1234525281]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The results of extensive investigations show AMHRII expression in a majority of tumor samples in a wide range of non-gynecological tumors such as colorectal and lung cancers, hepatocarcinoma or renal cell carcinoma. Moreover internalization capabilities and selective distribution of the target have been utilized to design a first AMHR2 based ADC approach.
The presentation details are as follows:
• Title: Anti-Müllerian Hormone type II Receptor (AMHRII) found expressed in
human non-gynecological solid tumors, suggesting potential broader applications
for anti-AMHRII-based therapy
o Abstract number: 774
o Date and time: April 15, 2018, 1pm – 5pm (CT)
o Session category/title: Experimental and Molecular Therapeutics
o Location: Section 36
• Title: Anti-Müllerian hormone type II receptor (AMHRII), a cancer target for
GM103, a novel antibody-drug conjugate (ADC)
o Abstract number: 1779
o Date and time: April 16, 2018, 8am – 12pm (CT)
o Session category/title: Therapeutic Antibodies, including Engineered
Antibodies 1
o Location: Section 34
The studies were performed with GamaMabs’ partners, including the Curie Institute (Paris, France), the Gustave Roussy Institute (Villejuif, France), Massachusetts General Hospitals (Boston, USA), the Léon Bérard Cancer Center (Lyon, France), Nantes University Hospital (France), the Montpellier Cancer Research Institute (France), Abzena (UK) and the Helsinki University Hospital (Finland).
"We are happy to be able to share such groundbreaking data on AMHRII expression, unveiling its potential as a novel target in a wide range of solid tumors," said Jean-François Prost, VP R&D at GamaMabs. "The results with GM103 clearly show, as a proof of concept, that AMHRII is also a suitable target for treating AMHRII-positive solid tumors with an ADC."
"We are committed to expanding our development plans beyond gynecological cancers, in particular for our lead program GM102," said Stéphane Degove, CEO at GamaMabs. A copy of the above referenced abstracts can be viewed online through the AACR (Free AACR Whitepaper) meeting website. Following the presentation, the data presented will be available on the Publications page of GamaMabs’ website.